Does Mounjaro or Wegovy cause muscle loss?
Yes, Mounjaro and Wegovy can be associated with some loss of lean mass while body weight falls. That does not mean either medicine directly targets muscle tissue or “burns muscle” as its main effect.
Mounjaro contains tirzepatide. Wegovy contains semaglutide. Both are prescription-only weight-loss medicines used alongside diet and physical activity in adults who meet the relevant clinical criteria. Their official UK medicine information describes appetite-related effects: feeling fuller, feeling less hungry and experiencing fewer food cravings. [1][3]
When appetite falls, total food intake often falls too. That calorie deficit is what drives weight loss. The body usually loses mostly fat, but some non-fat tissue may fall as well, especially if someone eats too little protein, stops using their muscles, loses weight rapidly or struggles to maintain regular meals.
The useful question is not “does the medicine eat muscle?” It is “what proportion of weight loss is fat, what proportion is lean mass, and what can I do to protect strength?”
What the body-composition studies show
The best available evidence comes from body-composition substudies rather than scale weight alone. These studies are useful, but they are not a perfect head-to-head comparison between Mounjaro and Wegovy. They used different study designs, populations and measurement methods.
|
Treatment
|
Evidence
|
What it showed
|
Plain-English meaning
|
|
Mounjaro / tirzepatide
|
SURMOUNT-1 DXA body-composition analysis
|
Of the body weight lost, approximately 75% was fat mass and 25% was lean mass. [5]
|
Most weight lost was fat, but lean mass still fell.
|
|
Wegovy / semaglutide
|
STEP 1 exploratory DXA analysis
|
Body weight fell by 15.0% with semaglutide; total fat mass fell by 19.3%; total lean body mass fell by 9.7%; the proportion of lean body mass increased by 3.0 percentage points. [6]
|
Fat mass fell more than lean mass, so body composition improved overall.
|
|
Comparison
|
No definitive DXA head-to-head answer
|
The evidence does not prove that one medicine is categorically “safe for muscle” and the other is not.
|
Choice of treatment should not be based on muscle-loss fear alone.
|
Lean mass is not the same as muscle
This distinction matters. In body-composition research, “lean mass” is not the same thing as skeletal muscle alone. Expert terminology guidance separates fat mass, fat-free mass, lean soft tissue and skeletal muscle, because they are different body components measured at different biological levels. [7]
In practical terms, a fall in lean mass may include some muscle, but it can also reflect changes in water, glycogen and other non-fat tissue. This is why a body-composition result should not be interpreted as proof that every kilogram of “lean mass” lost is a kilogram of contractile muscle.
That said, muscle still matters. Skeletal muscle supports strength, mobility, glucose handling, posture, daily function and longer-term weight maintenance. It is sensible to protect it from the start of treatment rather than trying to recover it later.
Is Mounjaro worse than Wegovy for muscle loss?
There is no simple, clinically settled answer. Tirzepatide often produces larger average weight loss than semaglutide in obesity trials, so the absolute amount of lean mass lost can be larger if total weight loss is larger. But that does not automatically mean Mounjaro is uniquely muscle-wasting or that Wegovy protects muscle by default. [12][13]
A 2026 pre-peer-review observational analysis, reported by Reuters, suggested that people using tirzepatide lost more lean body mass than people using semaglutide. The same report noted that the study had not yet been peer reviewed and used a mixture of scans and smart-scale estimates. Treat this as an emerging signal, not as a reason to start, stop or switch treatment without clinical advice. [14]
For most patients, the more useful approach is to match the medicine to clinical suitability and then build a muscle-protection plan around nutrition, strength training and follow-up.
Why muscle or lean mass can fall during GLP-1 weight loss
Lean mass loss is not unique to Mounjaro or Wegovy. It can happen with any substantial weight loss, including diet-led weight loss, bariatric surgery and medicine-supported weight loss.
The risk increases when several things happen together: appetite falls sharply, meals become too small, protein intake drops, the person becomes less active, and there is no regular resistance training signal telling the body to keep muscle tissue. The Mounjaro SmPC also states that reduced food intake contributes to body weight loss and that weight reduction is mostly due to reduced fat mass. [2]
This is one reason very fast, under-fuelled weight loss is not the goal. The aim is not simply to make the number on the scale fall. The aim is to reduce excess fat while preserving function, strength and health.
How to protect muscle while taking Mounjaro or Wegovy
Muscle protection is not a single trick. It is the combination of enough protein, progressive muscle use, sensible calorie restriction and good clinical follow-up.
1. Make protein deliberate
The UK baseline adult protein reference intake is 0.75 g per kg of body weight per day, but that is a population baseline, not a personalised weight-loss or strength-training target. [10]
During active weight loss, many people need a more deliberate protein strategy. A 2024 systematic review and meta-analysis in adults with overweight or obesity found that enhanced protein intake helped retain muscle mass during weight loss, and that intakes above 1.3 g/kg/day were associated with better muscle-mass outcomes than lower intakes. [8]
A practical target should be personalised. Body weight, kidney health, age, activity level, appetite, nausea, food preferences and dietary pattern all matter. If you have kidney disease, a history of eating disorder, complex medical conditions or very low appetite on treatment, ask your prescriber, GP or dietitian before pushing protein higher.
2. Strength train at least twice a week
The NHS recommends adults do strengthening activities for all major muscle groups on at least two days a week. [9]
For muscle retention, this matters more than simply “being active”. Walking and cardio are useful for health, but resistance training gives the clearest signal to keep and rebuild muscle. That can mean weights, machines, resistance bands, bodyweight exercises or supervised gym work. Start at a level that matches your joints, confidence and current fitness, then progress gradually.
3. Avoid turning appetite suppression into severe restriction
Mounjaro and Wegovy can make eating less feel easier. That does not mean eating as little as possible is a good plan.
If meals become too small, protein drops, or nausea makes food difficult, the risk is not only muscle loss. You may also feel weak, constipated, dizzy, tired or unable to train. Speak to your prescriber if side effects or appetite suppression stop you eating regular, nourishing meals.
4. Track strength, not just weight
Scale weight is useful, but it is blunt. A better picture comes from combining weight trend with waist measurement, strength, function, protein intake and how well you are managing meals.
Smart scales can be directionally useful, but they are not exact medical measurements. DXA scans can be more informative, but even DXA needs careful interpretation because lean mass is not pure muscle. Use any body-composition tool as a trend, not as a verdict.
What to track if you are worried about muscle loss
Use tracking to support a conversation with your prescriber or clinician. Do not use it to punish yourself or chase the fastest possible weight loss.
|
What to track
|
How often
|
Why it matters
|
What to do with it
|
|
Weight trend
|
Weekly average, not daily panic readings
|
Shows whether loss is very rapid, stalled or steady
|
Discuss very rapid loss or symptoms with your prescriber
|
|
Waist or clothing fit
|
Every 2–4 weeks
|
Helps separate fat-loss progress from water and scale changes
|
Use alongside weight and strength, not instead of them
|
|
Strength markers
|
A few repeatable exercises: sit-to-stand, press, row, squat pattern, carrying ability
|
Falling loads, reps or daily function may suggest under-fuelling or deconditioning
|
Review food intake, protein and training plan
|
|
Protein and meal rhythm
|
Most days during active weight loss
|
Low appetite can make protein intake drift down without you noticing
|
Ask for help if you cannot manage regular meals
|
|
Function and symptoms
|
Energy, dizziness, weakness, falls, persistent nausea or vomiting
|
These affect safety, nutrition and treatment adherence
|
Contact your prescriber or GP promptly if persistent, worsening or affecting daily life
|
When to ask for clinical or nutrition support
Ask for help early if you are losing strength, feeling persistently weak, struggling to eat enough, avoiding food because of nausea, or becoming anxious about every calorie or scale change.
You should also ask for individual advice before making major protein changes if you have kidney disease, significant medical conditions, a history of eating disorder, frailty, older age with low muscle reserve, or medicines that affect appetite, digestion, blood glucose or fluid balance.
Do not start, stop, increase, reduce or switch Mounjaro or Wegovy to manage muscle-loss worries without advice from your prescriber. Treatment choice and dose decisions need your medical history, side effects, response and safety profile to be reviewed together.
The practical answer
Mounjaro and Wegovy can both reduce lean mass as weight falls, but the available body-composition evidence shows that most of the weight lost is fat. The risk is not that these medicines simply strip muscle away. The risk is that treatment works so well on appetite that people can under-eat, under-protein and under-train unless they have a sensible plan.
The goal is not the smallest body at any cost. The goal is clinically supported fat loss with strength, mobility and long-term health protected along the way.
